Eli Lilly, Insulet to develop Humulin-specific OmniPod

Insulet ($PODD), creator of the OmniPod tubeless insulin pump, joined forces with Eli Lilly ($LLY) this week to develop a version of the device designed to deliver Lilly's Humulin R U-500 insulin. The highly concentrated form of insulin allows patients with resistant Type 2 diabetes to administer large doses in a reasonable volume, according to Insulet, and if ensuing clinical trials prove its safety and efficacy, the Omnipod would be the first insulin pump specifically for Humulin R U-500. Insulet touts the FDA-approved device as the "world's first tubeless insulin pump." Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

A self-injection pen prefilled with Brussels-based UCB’s Cimzia (certolizumab pegol) has been made available this week in the U.K. after a positive opinion…

Everstone, a private equity firm specializing in India and Southeast Asia, has finally decided to shell out Rs 220 crore ($33 million) to obtain a 70% stake--a…